Medicus Pharma Ltd

Contributing Author

Recent Articles by Medicus Pharma Ltd

7 hours	Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort MDCX -52.10% GlobeNewswire
Mar-03	Medicus Pharma To Participate in the 38th Annual Roth Conference MDCX GlobeNewswire
Feb-10	Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk MDCX GlobeNewswire
Jan-22	Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile MDCX GlobeNewswire
Jan-20	Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 MDCX GlobeNewswire
Jan-12	Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women MDCX -5.81% GlobeNewswire
Jan-05	Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates MDCX GlobeNewswire
Dec-15	Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin MDCX GlobeNewswire
Nov-24	Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers MDCX -7.04% GlobeNewswire